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For over 25-years the standard 4-drug, short-course, regimen of 6 months rifampicin (R) 
and isoniazid (H) supplemented by pyrazinamide (Z) and ethambutol (E) for the first 2 
months has been established as the treatment for drug-sensitive tuberculosis (TB); and 
enshrined in all recent national and international guidelines.  However, as drug 
susceptibility testing undergoes a shift to genotypic methods that offer the possibility of 
rapid drug susceptibility information for increasing numbers of drugs, the case for deviating 
from this standardised approach to a more individualised one is emerging. In particular, the 
routine use of ethambutol could be discontinued.    
 
Central to the current, short-course regimen are the sterilizing actions of pyrazinamide and 
rifampicin. By the late 1980s randomised trials had demonstrated that these drugs in 
combination with isoniazid in a 6 month regimen (2HRZ/4HR) were sufficient to achieve a 
relapse rate of less than 4% which was not improved by addition of a fourth drug(1-3).  The 
rationale for retaining a fourth drug has been largely as an insurance against undiagnosed 
isoniazid resistance, present in 8% of the world’s TB cases (as rifampicin-sensitive, 
isoniazid-resistant disease), ensuring that at least 3 effective drugs are being provided in 
the intensive phase(4).  However, the standard, 4-drug, regimen in those with isoniazid 
mono-resistance has been shown to lead to unacceptably high rates of treatment failure 
(11%) and acquired rifampicin resistance (8%), meaning that identifying isoniazid resistance 
and then modifying therapy remains critical(5).  Recent WHO guidelines recommend these 
patients receive 6 months of 4 effective drugs (rifampicin, pyrazinamide, ethambutol and 
levofloxacin), though further trials in this area are needed(4).   
 
The CRyPTIC consortium has recently published findings demonstrating that Whole 
Genome Sequencing (WGS) can be used to predict susceptibility to the first-line TB 
drugs(6).  This has led to the UK, the Netherlands and New York State, suspending or 
planning to suspend phenotypic susceptibility testing for isolates predicted by WGS as 
sensitive; and it will only be a matter of time before other countries follow suit.   
 
Recent work on the programmatic turnaround time in the UK has shown that drug 
susceptibility information by WGS is available within 8 days of receipt of a cultured isolate, 
substantially faster than phenotypic results(7).  Although at present WGS is only performed 
following culture, in the near future it is likely that direct sequencing from sputum will 
reduce the turn-around time for susceptibility information to a matter of days from sample 
collection(8). 
 
In most countries, over 90% of cases of tuberculosis are susceptible to the 4, first-line 
drugs, hence ethambutol for these individuals will not provide any additional benefit and 
may contribute to harm, health service costs and drug resistance.  Ethambutol can add a 
further 2-5 tablets to the daily pill burden if the 4-drug fixed-dose combination (FDC) is not 
used, and can have an unpleasant metallic taste.  Both pill burden and adverse effects are 
significant contributors to regimen non-adherence.  Optic neuritis is a relatively uncommon 
complication of ethambutol particularly at the 15mg/kg dose; however, the visual screening 
conducted at baseline contributes to health service burden. In addition, although the 
regimen cost for drug-sensitive TB is low, depending on the FDC used, ethambutol can 
contribute up to 60% of the drug cost of the intensive phase of therapy.   
 
However, perhaps the most compelling case for the rational use of ethambutol is drug 
resistance.  Recent surveys suggest up to 65% cases of multi drug-resistant (MDR) TB 
(resistant to at least rifampicin and isoniazid) are also resistant to ethambutol(9).  
Ethambutol resistance is driven by exposure to the drug as part of the primary regimen, 
limiting its utility in the management of MDR-TB.  Therefore, a more rational use of first 
line drugs now, could potentially lead to increasing options for the management of future 
drug-resistant TB.      
 
As diagnostics improve, there is a strong case for using drugs more wisely. At present over 
90% of people are over-treated with the first-line regimen, whilst there is systematic under-
treatment of patients with isoniazid mono-resistance, particularly in settings reliant on 
Xpert-MTB/RIF (which is unable to detect isoniazid mono-resistance, and has in some 
places led to a reduction in phenotypic drug susceptibility testing). As complete first-line 
susceptibility predictions are available ever more rapidly and widely, we need to reflect on 
the rationale for our current treatment approach, and adapt our practice and guidelines. 
Prompt cessation of ethambutol once first-line drug susceptibility is predicted would 
benefit patients and health systems now. As direct-from-sample sequencing, or alternative 
methodologies, start to deliver more rapid prediction of susceptibility and resistance to all 
first-line drugs, further opportunities to initiate truly individualised therapy, and realise yet 
more benefit, will arise. 
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